Editorial: Omics solutions for endocrine disorders

Multifactorial processes contribute to the development of endocrinological disorders such as diabetes, polycystic ovary syndrome (PCOS) and some carcinomas. Frequently, standard clinical tests are insufficient for proper diagnosis and treatment. Therefore, strategies providing further insight into endocrinological disorders that support the clinical pipeline are required. Recently, omics technologies such as genomics, transcriptomics, proteomics, metabolomics and lipidomics have been introduced into the field of complex disorders to improve diagnostics and treatment. This special edition highlights the use of omic technologies in endocrinological disorders, including diabetes and its comorbidities, as well as obesity and PCOS, further emphasizing their potential to be implemented into the clinical pipeline. What this special edition also emphasizes is the differing methodology available for each of the “omic” approaches that may not be directly comparable, one example being in proteomics where some groups use aptamer-based technology whilst others may use mass spectroscopy, and therefore the need for standardization.